Dauer

Smith + Howard Announces Addition of Marty Dauer as Chief Growth Officer

Retrieved on: 
Tuesday, March 19, 2024
SOC, Marsh McLennan, Growth, Dauer, Tyco International, Duff & Phelps, Smith, Acquisition, Multimedia, Marketing, Management

ATLANTA, Ga., March 19, 2024 /PRNewswire-PRWeb/ -- Smith + Howard, a leading Atlanta-based tax, accounting, and advisory firm, is pleased to announce the appointment of Marty Dauer as Chief Growth Officer, a newly created role. Dauer will focus on the expansion of the Smith + Howard Family of Companies through the identification of new service lines and markets, as well as the development of strategic relationships.

Key Points: 
  • Smith + Howard, a leading Atlanta-based tax, accounting, and advisory firm, is pleased to announce the appointment of Marty Dauer as Chief Growth Officer, a newly created role.
  • ATLANTA, Ga., March 19, 2024 /PRNewswire-PRWeb/ -- Smith + Howard, a leading Atlanta-based tax, accounting, and advisory firm, is pleased to announce the appointment of Marty Dauer as Chief Growth Officer, a newly created role.
  • Dauer will focus on the expansion of the Smith + Howard Family of Companies through the identification of new service lines and markets, as well as the development of strategic relationships.
  • "The addition of Marty Dauer to our team adds deep knowledge and experience in areas critical to the future expansion of our business," said Sean Taylor, CEO of Smith + Howard, when announcing Dauer's appointment.

DGAP-News: Atriva Therapeutics Announces Changes to Advisory Board

Retrieved on: 
Wednesday, January 20, 2021
Dauer, Lichtenberger, Advisory board, ATR-002's mode of action with dual benefit, Atriva Therapeutics GmbH

The Company appointed Dr. Ulrich Dauer as new Chairman of the Advisory Board succeeding co-founder Prof. Dr. Stephan Ludwig who will continue to serve on the Advisory Board of Atriva Therapeutics.

Key Points: 
  • The Company appointed Dr. Ulrich Dauer as new Chairman of the Advisory Board succeeding co-founder Prof. Dr. Stephan Ludwig who will continue to serve on the Advisory Board of Atriva Therapeutics.
  • Prof. Ludwig will continue to offer his scientific insight and expertise as virologist in the Advisory Board, which are highly valuable for our future development," said Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, continuing: "With Dr. Ulrich Dauer and Michael Grissinger we were able to attract two accomplished sector specialists to our Advisory Board.
  • "I am excited to support Atriva," said Dr. Ulrich Dauer, Chair of Atriva's Advisory Board.
  • "Looking ahead, securing pandemic preparedness will be crucial for humankind, and Atriva Therapeutics could play a central role in it.